Drugs / LXP1788
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06883539 | Dec 2024 → Dec 2027 expected | hepatocellular carcinoma, malignant pancreatic neoplasm, renal cell carcinoma | LaunXP Biomedical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LXP1788 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06883539 ↗ |
| Known as | LXP1788 Injection | “LXP1788 Injection is formulated as a solution for injection and will be administered intravenously for 60 minutes on days 1, 8, 15, 22 of the cycle. Each cycle will be 28 days.” NCT06883539 ↗ |
| Route | Intravenous | “administered intravenously” NCT06883539 ↗ |